MedTrace Logo

Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine

NCT00602784 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2012-10-19

No results posted yet for this study

Summary

The objectives are

1. to determine the immunological profile (CD4+, CD8+ cells, DTH) induced by immunization with HCV antigen peptide vaccine with polyarginine.
2. to document virological (HCV-RNA) and biochemical (ALT) responses following immunization with HCV antigen peptide vaccine with polyarginine.
3. to assess the safety of immunization with HCV antigen peptide vaccine with polyarginine.

Conditions

  • Chronic Hepatitis C

Interventions

BIOLOGICAL

IC41

Sponsors & Collaborators

  • Valneva Austria GmbH

    lead INDUSTRY

Principal Investigators

  • Erich Tauber, M.D. · Valneva Austria GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2004-05-31
Completion
2004-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00602784 on ClinicalTrials.gov